Loading...
West Pharmaceutical Services reported a 2.3% increase in revenue for Q4 2024, driven by strong demand for high-value self-injection devices. However, EPS declined slightly due to higher costs and currency headwinds.
West expects 2025 revenue to grow 2-3% organically, driven by self-injection devices, biologics, and GLP-1 therapies. However, currency exchange and cost pressures may weigh on earnings.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance